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Testicular cancer represents the more frequent solid tumor affecting males aged 15–35
years. In the last decades, its incidence showed a progressive increased probably due
to genetic and environmental factors. Despite exposure to some viruses such as HIV,
HCV, EBV, and HPV is frequently related to cancer development, there are no studies
aimed to evaluate the possible implication of viral infections in the pathogenesis of
testicular cancer. In this study, we analyzed sperm parameters and prevalence of HPV
on sperm in 155 testicular cancer patients at diagnosis (T−1), after orchiectomy (T0)
and after 12 months from surgery or from the end of adjuvant treatments (T12). All
patients showed a significantly higher prevalence of semen infection than controls (9.5%
and 2.4% respectively,) and altered sperm parameters both at T−1 and T0. Considering
sperm parameters, at T−1 we observed a reduction of progressive motility, and after
orchiectomy patients showed a reduction of sperm concentration and count and a further
worsening of motility. Thereafter, patients were assigned to three groups on the basis of
medical option after surgery: S = surveillance, R = radiotherapy, and C = chemotherapy
+/− radiotherapy. At T12, untreated patients had an improvement of sperm parameters
while R group and even more C group had a strong decrease of sperm number (p < 0.01
both vs. T0 and S group). Moreover, patients who received radio and/or chemotherapy had
a very high prevalence of HPV semen infection (S = 7.7%, R = 30.8%, and C = 61.5%).
In conclusion, patients with testicular cancer had frequently altered sperm parameters
and higher prevalence of HPV semen infection that were worsened after radio and
chemotherapy. Because HPV infection is a risk factor for cancer development and it may
further reduce fertility, we suggest screening for HPV in testicular cancer patients at
diagnosis and particularly after adjuvant treatments.
Keywords: chemotherapy, human papillomavirus, male infertility, radiotherapy, sexual transmitted diseases,
sperm infection, sperm parameters, testicular cancer
INTRODUCTION
Testicular cancer represents a rare pathology, accounting for
about 2% of total cancer. However, considering men aged 15–35,
it becomes the most common solid malignancy (Siegel et al.,
2012; Viatori, 2012). Moreover, many authors demonstrated an
increasing secular trend especially in some regions of Europe and
North America (Adami et al., 1994; Richiardi et al., 2004; Zoltick,
2011). Many risk factors have been studied as a pre-disposing
factor in the development of this cancer, but only for some
there is a high level of evidence (Senturia, 1987; Buetow, 1995).
Conditions particularly involved are cryptorchidism, previous
contralateral testicular cancer, family history and the presence of
gonadal dysgenesis (Dieckmann and Pichlmeier, 2004; McGlynn
and Trabert, 2012). Although many genital cancers are closely
related to Papillomavirus (HPV), to date no study evaluated the
possible role of viruses in the pathogenesis of testicular cancer.
HPV is one of the most common sexually transmitted infections
(STIs), it is particularly common in young sexually active pop-
ulation and its prevalence is closely related to sexual behavior
(Dillner et al., 2000). HPV was found, from a long time, in a high
percentage of genital benign lesions as warts and condylomata
and carcinomas (Gissmann, 1984; Shah and Buscema, 1988).
In particular is well-established the etiologic role of high-risk
HPV types in the carcinogenesis of the vulva, vagina, penis, anus,
head, neck, and oropharyngeal cavity (Backes et al., 2009; Smith
et al., 2009; Guily et al., 2011). Recently, we reported a signif-
icant presence of (HPV) DNA in thawed semen samples from
patients with testicular cancer who cryopreserved semen (Foresta
et al., 2010). This finding was confirmed by other authors show-
ing similar data from patients who banked their sperm because of
chemo/radiotherapy (Kaspersen et al., 2011). These data are very
important because cryopreserved semen samples, especially when
patients undergo therapies that can affect spermatogenesis, are
frequently used by assisted reproductive techniques, such as intra-
cytoplasmic sperm injection (ICSI). It has been observed that the
bond between virus and sperm is very strong and that conven-
tional washing procedures aimed to select sperm before in vitro
fertilization (IVF) have low efficacy in eliminating HPV sperm
infection (Foresta et al., 2011a; Garolla et al., 2012). In addition,
we demonstrated that artificially infected sperm, both transfected
with E6/E7 HPV genes and incubated with viral proteins, are able
to enter the oocyte, to deliver HPV genome, and that viral genes
are then actively transcribed by the penetrated oocyte (Foresta
et al., 2011b). Furthermore, a recent study showed that HPV
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infected couples undergoing assisted reproduction techniques
(ART) cycles experienced an increased risk of pregnancy loss
compared to non-infected ones (Perino et al., 2011). In these cou-
ples the more predictive factor of early abortion was represented
by HPV sperm infection. An important risk factor for HPV infec-
tion is the presence of immunosuppression status. Patients with
cancer, particularly after adjuvant therapies, as chemotherapy and
radiotherapy can be immunosuppressed and therefore at higher
risk for this infection (Rasmussen and Arvin, 1982; Bieber et al.,
2006; Fallahian et al., 2010). Despite the large body of literature
concerning the role of HPV in many cancer types, very little is
known about this viral infection and testicular cancer. In the light
of these considerations, we evaluated semen parameters and the
prevalence of HPV semen infection in a large group of patients
with testicular cancer at diagnosis, after orchiectomy and after
further 12 months of surveillance or after the end of radiother-
apy and/or chemotherapy. In subjects with HPV semen infection,
we evaluated also the percentage of infected sperm.
MATERIALS AND METHODS
PATIENTS
Written informed consent was obtained from all patients, and
the study protocol was approved by the local ethics committee.
We enrolled 155 consecutive patients affected by testicular cancer
candidate to unilateral orchiectomy, who attended the Centre for
Human Reproduction Pathology for andrological examination. A
medical history including previous circumcision, smoking, and
sexual behavior was obtained from each patient. As control sub-
jects, we used a group of 84 healthy proven fertile men. All
subjects collected semen for standard semen analysis, detection
of HPV DNA and fluorescence in situ hybridization (FISH) for
HPV at diagnosis and 1 month after orchiectomy. Therefore,
patients who underwent chemo and/or radiotherapy were reeval-
uated after 12 months from the end of treatments. Patients who
were followed-up just by surveillance repeated the same analysis
after 12 months from surgery.
SEMEN PROCESSING
Semen samples were obtained by masturbation after 3 days
of sexual abstinence. After liquefaction at room temperature,
semen volume, pH, sperm concentration, viability, motility, and
normal morphology were determined following World Health
Organization guidelines for semen analysis (WHO, 2010). An
aliquot was used for further analysis.
HPV DNA DETECTION
The presence of HPV infection was detected by PCR amplifica-
tion of HPVDNAwith SPF10 primers and then genotyped by the
INNO-LiPA HPV Genotyping Extra assay (Innogenetics, Gent,
Belgium), which can identify the following HPV genotypes: HPV-
6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54,
56, 58, 59, 66, 68, 69/71, 70, 73, 74, and 82 (Eklund et al., 2010).
SPERM FLUORESCENCE in situ HYBRIDIZATION (FISH) FOR HPV
Samples containing at least 2 × 106 ejaculated sperm were fixed
in a methanol-acetic acid solution for at least 1 h at −20◦C.
To permeabilize, samples were digested with pepsin diluted
1:25,000 in pre-warmed 0.01 mol/L-1 HCl for 10min at 37◦C.
Permeabilization of the specimens was stopped with 3–5-min
washes in PBS 1×; then samples were dehydrated in 70%, 80%,
and absolute ethanol for 2min and finally air-dried. Samples
were then overlaid with 20mL of hybridization solution (Pan
Path, Amsterdam), containing biotin-labeled HPV DNA probe
(a mix of total genomes containing the conserved HPV region).
Each slide was covered with a glass coverslip, and the edges were
sealed with nail polish to prevent loss of the mixture during
denaturation and hybridization. After a simultaneous denatura-
tion of cellular target DNA and HPV DNA probe on a heating
block for 5min at 95◦C, hybridization was performed by incu-
bating the samples at 37◦C overnight in a humidified chamber.
Thereafter, the coverslips were carefully removed and the slides
were washed in PBS 1× for 10min. After 15min incubation at
37◦C with the differentiation reagent (Pan Path), the slides were
washed three times in PBS 1×. The biotin-labeled HPV probe
was detected by incubation with 1:200 streptavidin Texas Red®
(Vector Laboratories, Burlingame, CA) for 40min at room tem-
perature. After detection, the slides were washed twice in PBS
1×/0.01% Triton and then twice in PBS 1× and mounted with
a solution containing 4′,6-diamidino-2phenylindole (DAPI) and
anti-fade (BioBlue, BioView Ltd., Nes Ziona, Israel). Samples
were analyzed using a fluorescence microscope (Nikon ViCo
Video Confocal Microscope) equipped with a triple bandpass
filter set (FITC, TRITC,DAPI). For each slide, at least 200 sperma-
tozoa were analyzed. Evaluation of nuclear hybridization signals
was performed in triplicate by different investigators. In sam-
ples that resulted negative during the follow-up, results were
confirmed by PCR. When nuclei were completely and homoge-
neously stained and multiple small spots or single large signals
were present, the sperm cells were classified as positive. The
method was tested on control slides containing CaSki cells, a
human cervical carcinoma cell line with stably integrated and
transcriptionally active HPV genomes, which served as a con-
trol for the specific probe. Cells smeared on salinated glass
slides were fixed with 4% paraformaldehyde in PBS for 10min.
After fixation, cells were subjected to 3–5-min washes in PBS
1× and then dehydrated with 5-min ethanol washes (30%,
60%, and 95%). Cell smears were then air-dried and stored at
4◦C until use.
STATISTICAL ANALYSIS
The values shown are the averages of at least three evaluations
performed by different operators. Data regarding sperm parame-
ters were presented as mean ± SD while data on semen infection
as percentage. Differences between data were determined by two-
tailed Student’s t-test after acceptance of normal distribution
with the Kolmogorov-Smirnov test. Comparisons of proportion
were performed with a one-sided non-parametric resampling
test. P-values (two sided) <0.05 were considered statistically
significant.
RESULTS
Mean age of patients with testicular cancer was 31.2 ± 5.4 years,
not different from control subjects (30.8 ± 4.7 years). In Table 1
are reported sperm parameters andHPVDNAdetection in semen
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samples from controls and from patients evaluated before (T−1)
and 1 month after orchiectomy (T0). At T−1, patients showed
sperm concentration, count, and morphology not different from
controls, but a significant reduction of progressive motility (p <
0.05). After orchiectomy, we found a significant reduction of
sperm concentration and count (both p < 0.05 vs. T−1) and a
further reduction of spermmotility compared to T−1 and control
subjects (p < 0.01). Moreover, sperm volume and morphology
were not significantly different in patients compared with con-
trols before and after orchiectomy. Interestingly, the percentage
of subjects with HPV infection was higher among patients than
controls (9.7% vs. 2.4%). This percentage remained unchanged
at T0. After orchiectomy, patients were assigned to three groups
based on medical option: S = candidate to surveillance, R =
candidate to radiotherapy, and C = candidate to chemotherapy
with or without radiotherapy. In Table 2, are reported sperm
parameters, the percentage of patients with semen infection and
percentage of infected sperm observed in the three groups at T0
and after 12 months of surveillance or from the end of radio
and or chemotherapy (T12). At T0, considering patients from
different groups we found no difference in sperm parameters
and prevalence of HPV infection. Six patients were lost during
follow-up (4 from group S, 1 from group R, and 1 from group C),
therefore data at T12 are referred to the remaining 149 patients.
Considering patients as a whole, themean values of sperm param-
eters observed at T12 was not different from that at T0. However,
patients who underwent surveillance had a significant increase of
sperm number and motility compared to T0 (p < 0.05). In con-
trast, subjects who had radiotherapy showed no increase in sperm
number and reduced sperm motility compared to S group (p <
0.05). Moreover, patients who underwent chemotherapy associ-
ated or not with radiotherapy, had a reduction of both sperm
number and motility vs. T0 vs. patients from groups S (p <
0.05 and p < 0.01 respectively). In the three groups, we found
no significant differences in both ejaculate volume and normal
morphology comparing T12 with T−1 and T0. Considering all
patients, HPV semen infection was significantly higher in patients
at T12 respect to T0 (34.9% vs. 9.7%). By the comparison of dif-
ferent groups, the prevalence of infection resulted 7.7%, 30.8%
and 61.5% in S, R, and C groups respectively. Finally, patients
treated by chemotherapy had also a higher percentage of HPV
infected sperm compared to T0 and to S (both p < 0.05). In
Figure 1 there is an example of FISH analysis for HPV performed
in a semen sample from testicular cancer patients.
Table 1 | Sperm parameters and HPV DNA detection in semen samples from control subjects and patients at the time of diagnosis (T−1) and
1 month after orchiectomy (T0).
Ejaculate Sperm concentration Sperm count Progressive Normal Positive
volume (mL) (million/mL) (million) motility (%) morphology (%) PCR (%)
Controls (n = 84) 3.3 ± 0.8 46.9 ± 11.3 153.0± 53.1 53.4± 12.1 21.6 ± 6.4 2 (2.4)
T−1 (n = 155) 3.2 ± 1.3 40.1 ± 45.2 110.1 ± 125.3 34.2± 17.7∗ 18.9 ± 8.3 15 (9.7)∗
T0 (n = 155) 3.1 ± 1.3 19.8± 16.6∗∗,# 61.9 ± 45.5∗∗,# 31.2± 15.1∗∗ 18.5 ± 9.3 15 (9.7)∗
∗p < 0.05 vs. control subjects.
∗∗p < 0.01 vs. control subjects.
#p < 0.05 vs. T−1.
Table 2 | Sperm parameters, HPV DNA detection and FISH for HPV observed in testicular cancer patients 1 month after orchiectomy (T0) and
after 12 months (T12) from the end of any treatment.
Groups Ejaculate Sperm concentration Sperm count Progressive Normal Positive FISH on
volume (mL) (million/mL) (million) motility (%) morphology (%) PCR (%) sperm (%)
T0
S (n = 46) 2.9 ± 1.3 19.4± 14.4 54.6 ± 45.2 30.9 ± 14.1 19.8± 9.5 5 (11.1) 22.4 ± 8.3
R (n = 55) 3.2 ± 1.5 20.7 ± 19.7 67.1 ± 55.7 33.7 ± 17.6 17.9 ± 9.2 4 (7.2) 24.0 ± 3.7
C (n = 54) 3.1 ± 1.1 19.4± 15.2 62.7 ± 60.2 29.1 ± 12.9 17.9 ± 9.3 6 (10.9) 25.3 ± 3.8
Total (n = 155) 3.1 ± 1.3 19.8± 16.6 61.9 ± 45.5 31.2 ± 15.1 18.5± 9.3 15 (9.7) 24.0 ± 5.4
T12
S (n = 42) 3.1 ± 1.5 35.5 ± 25.7∗ 94.2 ± 93.5∗ 43.7 ± 18.2∗ 18.6± 10.1 4 (7.7) 24.9 ± 3.7
R (n = 54) 3.1 ± 1.7 23.8 ± 20.6 69.9 ± 58.7 30.8 ± 15.3# 18.0± 13.7 16 (30.8)∗,# 28.7 ± 6.0
C (n = 53) 3.3 ± 1.5 11.1 ± 9.9∗,## 24.4 ± 17.4∗,## 20.8 ± 14.2∗,## 17.1 ± 11.2 32 (61.5)∗∗,## 39.6 ± 8.2∗,#
Total (n = 149) 3.2 ± 1.5 22.6 ± 20.6 61.3 ± 50.5 30.7 ± 18.5 17.8 ± 11.5 52 (34.9)∗∗ 29.4 ± 6.9
Data are shown as total and subgrouping patients in: S group = patients who underwent surveillance, R group = patients who underwent radiotherapy, and
C group = patients who underwent chemotherapy followed or not by radiotherapy.
∗p < 0.05 vs. T0.
∗∗p < 0.01 vs. T0.
#p < 0.05 vs. S.
##p < 0.01 vs. S.
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FIGURE 1 | An example of FISH analysis for HPV performed on infected
semen samples from patients with testicular cancer. Red staining
indicates the presence of HPV DNA. (A) Negative semen sample.
(B) Infected semen sample.
DISCUSSION
It is of concern, especially during last years, the increasing inci-
dence of reproductive tract diseases and particularly testicular
cancer (Richardson et al., 2012). The latter disease is particu-
larly found among males aged between 15 and 40 years (Siegel
et al., 2012; Viatori, 2012) and, although it is a curable dis-
ease with a good prognosis, it is a major risk factor for fertility
(Jacobs and Vaughn, 2012). In fact, patients with testicular can-
cer have frequently a concomitant alteration of spermatogenesis
already at diagnosis, that can be further affected by chemo or
radiation therapies (Schrader et al., 2001; Bieber et al., 2006).
In this paper, we considered sperm parameters and prevalence
of HPV semen infection in testicular cancer patients pre- and
post-orchiectomy. Moreover, after 12 months we evaluated the
effect of different medical options on the same parameters. As
previously reported (Selice et al., 2011), in affected patients
we observed reduced sperm motility at diagnosis that was still
present 1 month after orchiectomy together with a significant
reduction of sperm number. Interestingly, we found that patients
at diagnosis had a significant increase of HPV semen infection
compared to controls. This finding could represent a cause of tes-
ticular cancer or an effect of this malignancy. Many hypotheses
have been raised regarding the possible cause of testicular cancer
development, as in utero and pre-pubertal exposure to endocrine
didisrupters, genetic predisposition, and environmental condi-
tions. Despite it is well-recognized that some viral infection have
a major role in the development of many cancers (EBV, HCV,
HPV, HIV etc.), this link has never been proposed for testicu-
lar tumors. On the other hand all tumors, including testicular
cancer, may induce an impairment of general health exposing
patients to infections. Moreover, testicular cancer patients after
orchiectomy may undergo to different medical options based
on type and tumor staging. Low risk conditions frequently
allow just surveillance, while conditions at higher risk are usu-
ally treated by adjuvant therapies. Patients from S group had
a significant improvement of sperm number and motility. This
finding suggests that the residual testis may have a compensatory
role after contralateral orchiectomy if patients are not exposed
to treatments affecting spermatogenesis. Far from many years,
it is well-known that both chemo and radiotherapies deeply
impair spermatogenesis and immune system. The results of this
study demonstrated that at T12 patients who received radio
and even more those who received chemotherapy had altered
sperm parameters both vs. pre-treatment vs. surveillance group.
The strong association between kind of treatment and sperm
alteration is further underlined by the comparison of sperm
parameters from different groups at T0. This analysis showed no
difference, suggesting that there was no relation between sperm
parameters and the degree of malignancy at diagnosis. In the
same way, adjuvant treatments resulted strongly related to HPV
infection susceptibility. In this study, we found that after surveil-
lance 7% of patients had HPV semen infection rising to 31% and
61% after radio and chemotherapy respectively. Therefore, drug-
mediated immunosuppression seems to be strictly related to HPV
seminal infection in testicular cancer patients. Finally considering
FISH analysis for HPV, beside a trend to increase in R group, we
observed a significantly higher percentage of infected sperm in
subjects who received chemotherapy. This is the first study evalu-
ating HPV sperm infection in semen samples from patients with
testicular cancer. By our findings we can conclude thatHPV infec-
tion is more prevalent in affected patients than controls. However,
as recently suggested by other authors (Bertazzoni et al., 2013),
this infection seems not to be cause of testicular cancer, but rather
the effect of a status of higher vulnerability induced by the tumor.
More and larger studies of follow-up of HPV infected patients
will clarify whether or not there is a cause-effect relationship
between HPV and testicular cancer or vice versa. Moreover, our
results demonstrated that treatments frequently used in testicu-
lar cancer patients and in particular chemotherapy, are able to
strongly increase the prevalence of HPV semen infection, prob-
ably through their immunosuppressive action. In conclusion, we
suggest testing spermHPV in patients affected by testicular cancer
before and particularly after treatments inducing immunosup-
pression, because this infection can in turn induce cancer inmany
sites and further reduce male fertility. Further and larger studies
are needed to confirm our findings also in patients affected by
other tumors.
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